Andrew J. Armstrong, Russell Zelig Szmulewitz, Daniel Peter Petrylak, Arnauld Villers, Arun Azad, Antonio Alcaraz et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): the ARCHES trial // J Clin Oncol. 2019. Vol. 37 (suppl, abstr 687). DOI: 10.1200/JCO.2019.37.7.
Andrew J. Armstrong, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer // J Clin Oncol. 2019. Vol. 37. P. 2974–2986. DOI: 10.1200/JCO.19.00799.
Anis Hamid, Xin Victoria Wang, Yu-Hui Chen, Felix Y. Feng, Robert Benjamin Den, Gerhardt Attard et al. Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): a correlative study of E3805 CHAARTED // J Clin Oncol. 2020. Vol. 38 (suppl, abstr 162). DOI: 10.1200/JCO.2020.38.6.
Arun A. Azad, Bernhard J. Eigl, R. Nevin Murray, Christian Kollmannsberger, Kim N. Chi. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients // Eur Urol. 2015. Vol. 67. P. 23–29. DOI: 10.1016/j.eururo.2014.06.045.
Axel Heidenreich, Patrick J. Bastian, Joaquim Bellmunt, Michel Bolla, Steven Joniau, Theodor van der Kwast et al. European Association of Urology. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer // Eur Urol. 2014. Vol. 65. P. 467–479. DOI: 10.1016/j.eururo.2013.11.002.
Bumbaca B., Li W. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies // Acta Pharm Sin B. 2018. Vol. 8. P. 518–529. DOI: 10.1016/j.apsb.2018.04.007.
Charles J. Ryan, Matthew R. Smith, Karim Fizazi, Fred Saad, Peter F.A. Mulders, Cora N. Sternberg et al. COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study // Lancet Oncol. 2015. Vol. 16. P. 152–160. DOI: 10.1016/S1470-2045(14)71205.
Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, Noel W. Clarke, Alex P. Hoyle, Adnan Ali et al. Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial // Lancet. 2018. Vol. 392. P. 2353–2366. DOI: 10.1016/S0140-6736(18)32486-3.
Christos E. Kyriakopoulos, Yu-Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Noah M. Hahn et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial // J Clin Oncol. 2018. Vol. 36. P. 1080–1087. DOI: 10.1200/JCO.2017.75.3657.
Clarke N.W., Ali A., Ingleby F.C., Hoyle A., Amos C.L., Attard G. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial // Ann Oncol. 2019. Vol. 30. P. 1992–2003. DOI: 10.1093/annonc/mdz396.
Daniel Khalaf, Matti Annala, Daygen L. Finch, Conrad D. Oja, Joanna Vergidis, Muhammad Zulfiqar, et al. Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): results for 2nd-line therapy // J Clin Oncol. 2018. Vol. 36 (suppl, abstr 5015). DOI: 10.1200/JCO.2018.36.15.
Daniel J. Khalaf, Katherine Sunderland, Bernhard J. Eigl, Christian K. Kollmannsberger, Nikita Ivanov, Daygen L. Finch et al. Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial // Eur Urol. 2019. Vol. 75. P. 940–947. DOI: 10.1016/j.eururo.2018.12.015.
Eisenberger M.A., Crawford E.D., Wolf M., Blumenstein B., McLeod D.G., Benson R. et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036 // Semin Oncol. 1994. Vol. 21. P. 613–619. URL: https://pubmed.ncbi.nlm.nih.gov/7939752/.
Flanagan J., Kathryn P. Gray, Hahn N., Hayes J., Myers L.J., Carney-Doebbeling C., Sweeney C.J. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer // Ann Oncol. 2011. Vol. 22. P. 801–807. DOI: 10.1093/annonc/mdq443.
Gerhardt Attard, Michael Borre, Howard Gurney, Yohann Loriot, Corina Andresen-Daniil, Ranjith Kalleda et al. PLATO collaborators. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment // J Clin Oncol. 2018. Vol. 36. P. 2639–2646. DOI: 10.1200/JCO.2018.77.9827.
Grace Lu-Yao, Nikita Nikita, Scott W. Keith, Ginah Nightingale, Krupa Gandhi, Sarah E. Hegarty et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities // Eur Urol. 2020. Vol. 77. P. 158–166. DOI: 10.1016/j.eururo.2019.07.031.
Gwenaelle Gravis, Jean-Marie Boher, Florence Joly, Michel Soulié, Laurence Albiges, Franck Priou et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer // N Engl J Med. 2015. Vol. 373. P. 737–746. DOI: 10.1056/NEJMoa1503747.
Gwenaelle Gravis, Jean-Marie Boher, Yu-Hui Chen, Glenn Liu, Karim Fizazi, Michael A. Carducci et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies // Eur Urol. 2018. Vol. 73. P. 847–855. DOI: 10.1016/j.eururo.2018.02.001.
Halabi S. Subgroup analysis in clinical trials. Paper presented at: Advanced Prostate Cancer Consensus Conference; August 2019. Basel, Switzerland.